7-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates. I am thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and for the continued su
31-Oct-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast a
7-Nov-2024 3:01 PM CST - Business Wire Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided corporate updates. I am thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and for the continued su
31-Oct-2024 3:01 PM CST - Business Wire Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended September 30, 2024 after the market close on Thursday, November 7 and will also host a conference call and webcast a